Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Rhea-AI Summary

Indivior PLC (NASDAQ/LSE: INDV) has acknowledged a letter published by Oaktree Capital Management to its Board of Directors. The Board confirms it has been actively engaging with Oaktree in recent weeks and maintains an open-minded stance regarding proposals for value creation. Indivior, a global pharmaceutical company focused on substance use disorders (SUD) treatment, emphasizes its commitment to acting in the best interests of all shareholders while executing its strategy. The company operates in over 30 countries and employs more than 1,000 people globally.

Argus Session date unavailable

+16.34% session move Open Argus

Details

News Market Reaction – INDV

The recorded move for INDV in the trading session of this news was +16.34%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.

The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation. The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy.

Indivior looks forward to further engagement with Oaktree and other shareholders. 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-responds-to-publication-of-a-letter-by-oaktree-capital-management-to-the-board-of-indivior-302299220.html

SOURCE Indivior PLC

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Indivior's response to Oaktree Capital Management's letter?

Indivior's Board acknowledged the letter and stated they have been actively engaging with Oaktree in recent weeks, maintaining an open-minded approach to value creation proposals while focusing on all shareholders' interests.

How many countries does Indivior (INDV) operate in?

Indivior's portfolio of products is available in over 30 countries worldwide.

What is Indivior's (INDV) main business focus?

Indivior is a global pharmaceutical company focused on developing medicines to treat substance use disorders (SUD) and transforming SUD from a global crisis to a recognized and treated chronic disease.